Mohammad Soroura, Maged El Shorbagy, M. Shawky, T. Borg, K. Wahba, A. Reyad
{"title":"Circulating Maternal Serum Cell Free Fetal DNA Levels for prediction of Preeclampsia","authors":"Mohammad Soroura, Maged El Shorbagy, M. Shawky, T. Borg, K. Wahba, A. Reyad","doi":"10.21608/ebwhj.2020.28158.1093","DOIUrl":null,"url":null,"abstract":"Background: Pre-eclampsia is a pregnancy-specific disorder that has a worldwide prevalence of 5–15%. It is one of the main causes of maternal and perinatal morbidity and mortality globally and accounts for 50 000–60 000 deaths annually, with a predominance in the low- and middle-income countriesThere is a great need to have a test for predicition of women at high risk of developing preeclampsia. Aim of the Work: to assess the accuracy of maternal serum Cff-DNA concentration levels in primigravidas 10-20 weeks gestation as a predictive test for the development of preeclampsia. Patients and Methods: A nested case-control study was conducted on 26 patients with PE and 26 matched controls rimigravidas in 10-20 weeks gestation recruited from Ain-Shams University Maternity Hospital. Laboratory work was done in Ali Khalifa laboratory of the biochemistry department, Faculty of Medicine, Ain-Shams University. Results: The study showed a statistically significant increase median of severe preeclampsia compared to non severepreeclampsia and control group according to cff-DNA (GE/ml). Also the study results revealed a statistically significant increase median of preeclampsia group compared to control group according to BMI, GA (wks), SBP and DBP. Conclusion: Cff-DNA quantification can be considered as a promising marker for preeclampsia prediction, especially for the development of early-onset or severe preeclampsia.","PeriodicalId":224226,"journal":{"name":"Evidence Based Womenʼs Health Journal","volume":"19 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2020-12-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Evidence Based Womenʼs Health Journal","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.21608/ebwhj.2020.28158.1093","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Pre-eclampsia is a pregnancy-specific disorder that has a worldwide prevalence of 5–15%. It is one of the main causes of maternal and perinatal morbidity and mortality globally and accounts for 50 000–60 000 deaths annually, with a predominance in the low- and middle-income countriesThere is a great need to have a test for predicition of women at high risk of developing preeclampsia. Aim of the Work: to assess the accuracy of maternal serum Cff-DNA concentration levels in primigravidas 10-20 weeks gestation as a predictive test for the development of preeclampsia. Patients and Methods: A nested case-control study was conducted on 26 patients with PE and 26 matched controls rimigravidas in 10-20 weeks gestation recruited from Ain-Shams University Maternity Hospital. Laboratory work was done in Ali Khalifa laboratory of the biochemistry department, Faculty of Medicine, Ain-Shams University. Results: The study showed a statistically significant increase median of severe preeclampsia compared to non severepreeclampsia and control group according to cff-DNA (GE/ml). Also the study results revealed a statistically significant increase median of preeclampsia group compared to control group according to BMI, GA (wks), SBP and DBP. Conclusion: Cff-DNA quantification can be considered as a promising marker for preeclampsia prediction, especially for the development of early-onset or severe preeclampsia.